GE HealthCare Technologies Inc. (NASDAQ:GEHC) Q4 2022 Earnings Call Transcript

Page 6 of 11

So that’s really how you should look at the quarterly flow for 2023.

Operator: Our next question comes from Veronika Dubajova with Citi. Your line is open.

Veronika Dubajova: Hi, good morning and thank you, guys, for taking my questions and congratulations on the successful spin as well.

Peter Arduini: Thanks, Veronika.

Veronika Dubajova: Maybe you guys can talk a little bit about the competitive environment that you’re seeing, and I’m thinking in particular in imaging and ultrasound. Curious if you’re seeing any changes. We saw one of your peers this morning canceled some historical orders, which they felt were at a lower price. Is that creating opportunities? Or in general, are you seeing opportunities that are driven by the disruption that this one peer of yours has suffered? And maybe specifically if you can comment on China and how the local strategy is playing out for you guys? Then I have one follow-up after that, but I appreciate this is a long question, so I’ll let you answer that first.

Peter Arduini: Yes, Veronika, I would say, look, from an environment in the marketplace, I would say a little bit just because of some of the dynamics here that there’s quite a bit of demand that’s actually out in the marketplace when you look at these backlogs of imaging procedures. And so all of the different players, I think, at some level are having some positive benefits of this market. I mean, again, the prioritization of the CapEx just doesn’t apply to GE HealthCare, right? It applies to everybody. And so we’re expecting that there’s a reasonable healthy amount of demand out there. And everyone at some level has had different experiences and challenges with their supply chain. So there is some similarities. At the same time, we think because of the investments that we’ve made over the past few years, we have some products that are winning share more so about the capabilities they bring to patients and customers than a situation where maybe one or two of our competitors are in.

And so I mentioned molecular imaging, where we’ve got leadership positions. What we’ve done in MR with our image quality as well as productivity, our CT surgery, what’s come out with ultrasound, that’s how we’re winning the day and in many cases, taking share in different marketplaces. I would say we are really being balanced about what we go after to make sure that we get the right margins and capability around. So that’s an important part of our overall strategy. I would say to your China question, look, there’s always been lots of local competitors. In many of our modalities for 10 to 20 years, there’s been 5x or 4x the amount of competition within China for China versus the rest of the world. And I think, as you know, we’ve been competing there for many, many years, manufacturing for over 30.

So we have a pretty good handle on it. And with some of the stimulus funds that were €“ the government put out really at the beginning of Q4, we’ve been seeing some robust demand for imaging equipment, in particular, both ultrasound and the whole spectrum of the imaging portfolio. And again, I think we’re going to see that continue into beginning of next year. And so we’ve been able to be quite successful we believe in competing against, both multinational as well as local competitors. We see ourselves, in many cases, as local €“ as a local player in many of our modalities again because of how we actually design and make products in China for China. You have another question?

Veronika Dubajova: Yeah, I did it, which was China specifically, if you can just remind us what proportion of your portfolio is certified as local now? And when might we hit 100%?

Page 6 of 11